FATE Material Contracts | FATE THERAPEUTICS INC

FATE THERAPEUTICS INC Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-06-15: Form 8-K; Exhibit 10.1; Description Third Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder.
2026-05-13: Form 10-Q; Exhibit 10.1; Description Amended and Restated Non-Employee Director Compensation Policy, effective March 31, 2026.
2025-11-13: Form 10-Q; Exhibit 10.1; Description Severance and Change in Control Policy, as currently in effect.
2025-10-14: Form 8-K; Exhibit 10.1; Description Offer Letter between the Company and Kamal Adawi, dated as of October 13, 2025.

Filed	Form	Exhibit	Description
2026-06-15	8-K	10.1	Third Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder
2026-05-13	10-Q	10.1	Amended and Restated Non-Employee Director Compensation Policy, effective March 31, 2026
2025-11-13	10-Q	10.1	Severance and Change in Control Policy, as currently in effect
2025-10-14	8-K	10.1	Offer Letter between the Company and Kamal Adawi, dated as of October 13, 2025
2025-08-12	10-Q	10.2	Amendment No. 5 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated June 13, 2025
2025-05-30	8-K	10.1	Second Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder
2025-03-05	10-K	10.41	Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd.
2025-03-05	10-K	10.5	Amended and Restated Non-Employee Director Compensation Policy
2025-01-06	8-K	10.1	Strategic Advisory Services Agreement between the Registrant and J. Scott Wolchko, dated as of December 31, 2024
2024-11-12	10-Q	10.2	Amendment No.4 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated August 28, 2024
2024-08-30	8-K	10.1	Amended and Restated Form of Indemnification Agreement
2024-06-07	8-K	10.1	Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder
2024-03-21	8-K	10.1	Securities Purchase Agreement, dated as of March 19, 2024, between Fate Therapeutics, Inc. and RedCo II Master Fund, L.P.
2024-02-26	10-K	10.42	Exclusive License Agreement, dated April 17, 2020, by an between the Registrant and Baylor College of Medicine
2024-02-26	10-K	10.41	Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd.
2023-08-08	10-Q	10.1	Amended and Restated Non-Employee Director Compensation Policy
2022-11-07	8-K	10.1	Letter Agreement, dated November 7, 2022, by and between Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd.
2022-08-03	10-Q	10.2	Amendment 01 to Collaboration and Option Agreement, dated June 28, 2022, by and between the Registrant and Ono Pharmaceutical Co. Ltd.
2022-02-28	10-K	10.40	License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc.
2021-08-04	10-Q	10.1	Amended and Restated Non-Employee Director Compensation Policy
2021-02-24	10-K	10.40	Patent License Agreement by and between the Registrant and Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, dated August 30, 2019
2021-02-24	10-K	10.39	Letter Agreement, dated December 4, 2020, by and between the Registrant and Ono Pharmaceutical Co., Ltd.
2021-02-24	10-K	10.22	License Agreement between the Registrant and The Scripps Research Institute, dated as of August 24, 2010
2021-02-24	10-K	10.21	License Agreement between the Registrant and The Scripps Research Institute, dated as of May 25, 2010
2021-02-24	10-K	10.20	License Agreement between the Registrant and The Scripps Research Institute, dated as of July 13, 2009
2021-02-24	10-K	10.19	Whitehead Institute for Biomedical Research Exclusive Patent License Agreement between the Registrant and the Whitehead Institute for Biomedical Research, dated as of February 24, 2009
2021-02-24	10-K	10.10	Forms of Restricted Stock Unit Award Agreement under Fate Therapeutics, Inc. Inducement Equity Plan
2021-02-24	10-K	10.9	Forms of Stock Option Agreement under Fate Therapeutics, Inc. Inducement Equity Plan
2021-02-24	10-K	10.8	Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan
2021-02-24	10-K	10.7	Amended and Restated Non-Employee Director Compensation Policy
2021-02-24	10-K	10.2	Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder
2020-08-19	8-K	10.1	Offer Letter between the Company and Edward J. Dulac III, dated as of May 20, 2020
2020-08-05	10-Q	10.3	Stock Purchase Agreement by and between the Registrant and Johnson & Johnson Innovation – JJDC, Inc., dated June 8, 2020
2020-08-05	10-Q	10.2	Stock Purchase Agreement by and between the Registrant and Johnson & Johnson Innovation – JJDC, Inc., dated April 2, 2020
2020-08-05	10-Q	10.1	Collaboration and Option Agreement by and between the Registrant and Janssen Biotech, Inc., dated April 2, 2020
2020-03-02	10-K	10.34	Lease Agreement by and between the Registrant and Scripps Summit Investments LLC, dated January 7, 2020
2020-03-02	10-K	10.8	Fate Therapeutics, Inc. Inducement Equity Plan
2020-03-02	10-K	10.7	Amended and Restated Non-Employee Director Compensation Policy
2019-03-05	10-K	10.38	Offer Letter by and between the Registrant and Bahram Valamehr, dated November 23, 2009
2019-03-05	10-K	10.33	Offer Letter by and between the Registrant and Cindy R. Tahl, dated October 23, 2009
2019-03-05	10-K	10.8	Fate Therapeutics, Inc. Inducement Equity Plan
2019-03-05	10-K	10.7	Amended and Restated Non-Employee Director Compensation Policy
2019-02-08	10-Q/A	10.2	Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd., dated September 14, 2018
2018-11-01	10-Q	10.2	Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd., dated September 14, 2018
2018-11-01	10-Q	10.1	Exclusive License Agreement by and between the Registrant and The J. David Gladstone Institutes, dated September 11, 2018
2018-08-06	10-Q	10.2	Amended and Restated Exclusive License Agreement by and between the Registrant and Memorial Sloan Kettering Cancer Center, dated May 15, 2018
2018-08-06	10-Q	10.1	Sixth Amendment to the Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated May 31, 2018
2018-05-10	10-Q	10.1	Employment Offer Letter by and between the Registrant and Chris M. Storgard, MD, dated April 27, 2016
2018-03-05	10-K	10.32	Severance and Change in Control Policy
2018-03-05	10-K	10.8	Fate Therapeutics, Inc. Inducement Equity Plan
2018-03-05	10-K	10.5	Amended and Restated Employment Agreement by and between the Registrant and Scott Wolchko, dated January 14, 2018
2017-08-14	10-Q	10.1	First Amendment to Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated July 14, 2017
2017-05-08	8-K	10.1	Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder
2016-11-22	8-K	10.2	Registration Rights Agreement, dated November 21, 2016, by and among the Company and the Purchasers
2016-11-22	8-K	10.1	Securities Purchase Agreement, dated November 21, 2016, by and among the Company and the Purchasers
2016-08-08	10-Q	10.2	Fifth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated June 1, 2016
2016-08-08	10-Q	10.1	Amended and Restated Non-Employee Director Compensation Policy
2016-08-08	8-K	10.2	Registration Rights Agreement, dated August 6, 2016, by and among the Company and the Purchasers
2016-08-08	8-K	10.1	Securities Purchase Agreement, dated August 6, 2016, by and among the Company and the Purchasers
2016-03-03	10-K	10.17	Sublease, dated December 15, 2014 by and between the Registrant and The Scripps Research Institute
2016-03-03	10-K	10.16	Fourth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated March 2, 2015
2016-03-03	10-K	10.15	Third Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated September 2, 2014
2016-03-03	10-K	10.5	Employment Agreement by and between the Registrant and Scott Wolchko, dated January 12, 2016
2015-11-06	10-Q/A	10.2	Amendment to Amended and Restated Investor Rights Agreement between the registrant and certain of its stockholders, dated as of May 4, 2015.
2015-11-06	10-Q/A	10.1	Collaboration and License Agreement between the registrant and Juno Therapeutics, Inc., dated as of May 4, 2015.
2015-08-05	10-Q	10.2	Amendment to Amended and Restated Investor Rights Agreement between the registrant and certain of its stockholders, dated as of May 4, 2015.
2015-08-05	10-Q	10.1	Collaboration and License Agreement between the registrant and Juno Therapeutics, Inc., dated as of May 4, 2015.
2015-03-12	10-K	10.26	CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURIT
2015-03-12	10-K	10.25	LICENSE AGREEMENT
2015-03-12	10-K	10.24	CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURIT
2015-03-12	10-K	10.23	CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURIT
2015-01-07	8-K	10.2	Form of Unrestricted Stock Award Agreement under the 2013 Stock Option and Incentive Plan
2015-01-07	8-K	10.1	Amended and Restated Senior Executive Incentive Bonus Plan
2014-08-05	8-K	10.2	Form of Warrant
2014-08-05	8-K	10.1	Amended and Restated Loan and Security Agreement, dated as of July 30, 2014, by and between the Company and the Bank
2014-01-10	8-K	10.1	Senior Executive Cash Incentive Bonus Plan

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
Lineage Cell Therapeutics, Inc. (LCTX)	United States	$0.241B	-10.35